ASCO 2017 Annual Meeting in Chicago

Chicago, IL – June 3, 2017

ASCO, the world’s largest cancer conference took place in Chicago from June 2-6. Mocuis (모크스) is in Chicago to meet with the nearly 40,000 oncology leaders. The conference attracts researchers, investors, health experts, and the biopharma to the annual event. Representatives from small to large global organizations present their findings and discoveries. This annual event highlights advancement in the treatment of cancer care in both therapies and health care.

If you would like to schedule a meeting with Mocuis, please email us at info@mocuis.com.

#ASCO17

 

Ilyang Pharmaceutical to export leukemia treatment to Colombia

Biopas
South Korea’s Ilyang Pharmaceutical Co. hammered out a deal with Laboratorios Biopas S.A., a Colombian pharmaceutical company, to export Supect (radotinib), its new drug developed to cure leukemia, according to Ilyang on Monday.

The final agreement between the two companies comes almost a year after they signed an initial agreement in August last year, which allows Biopas, the 10th-largest drug maker in Colombia, to sell Supect. The deal also comes with licensing fees and certain milestone payments worth $22 million in total.
read more>>

 
pulse_logo

BIO International Convention (BIO) 2016 in San Francisco

mocuis-bio-2016

San Francisco, CA – June 7, 2016

The 2016 BIO International Convention is well on its way. BIO runs from June 6-9 in the Moscone Center. This year there are over 15,000 biotech and pharma attendees, including 2,500+ CEOs from companies around the world. A record of more than 35,000 partner meetings have been scheduled through BIO’s 1×1 partnering system. Partnering and collaboration between biotech and pharmaceutical companies can bring innovative solutions to patient health. The topics covered at this event include drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

Mocuis (모크스) is attending BIO and we have been busy meeting leaders of the industry. If you would like to meet with Mocuis, please contact us at info@mocuis.com.

#BIO2016

 

ASCO Annual Meeting in Chicago

mocuis-asco-2016

Chicago, IL – June 3, 2016

Mocuis (모크스) is in Chicago for the 2016 ASCO (American Society of Clinical Oncology) Annual Meeting. Over 30,000 oncology professionals from around the world assemble in Chicago for the Annual Meeting discussing the leading treatments and therapies in the oncology field. The latest innovative research is also presented with over 500 exhibitors as well as almost 250 educational and scientific sessions. Mocuis is meeting with the foremost innovators in oncology therapies.

If you would like to schedule a meeting with Mocuis, please email us at info@mocuis.com.

#ASCO16

 

JP Morgan Healthcare Conference in San Francisco

SF-mocuis-banner

San Francisco, CA – January 14, 2016

The JP Morgan Healthcare conference was an energetic set of days where the setting was just as interesting outside of the conference as it was inside. The investor, biopharma, and healthcare execs convened at Union Square in San Francisco for the annual event. JP Morgan was expecting over 300 companies presenting to over 4,000 investors. Among the discussion was healthcare innovation, technology, and change. Mocuis (모크스) was in San Francisco conducting meetings and extending partnerships. It was an exciting time to connect with investors and industry leaders as well as looking forward to 2016.

#JPM16 #jpmorganhealthcare

Mocuis and Supect® in Orlando for ASH 2015

mocuis-ash-2015-hematology

Orlando, FL – December 8, 2015

The 2015 American Society of Hematology (ASH) annual meeting commenced in sunny Orlando, FL from December 5-8.  ASH brings the world’s leading hematology specialists in one location.  With over 20,000 people from every sub-specialty, ASH 2015 was a success. Mocuis (모크스) was in Orlando for the heralded event joining the hematology community in sharing their meaningful information and conclusions.

PS15120800511g_99_20151208142306

ⓒ종합 경제정보 미디어 이데일리

Attendees of ASH took part in IL-Yang Pharm’s presentation of Supect’s® (Radotinib HCl) compelling Phase III efficacy and safety results for newly diagnosed CML-CP patients. Supect is a second generation tyrosine kinase inhibitor (TKI) approved in South Korea as a first line treatment for newly diagnosed chronic myeloid leukemia chronic phase (CML-CP) and for the treatment of patients with Philadelphia positive chronic myeloid leukemia (Ph+ CML) without optimal response and/or tolerance to other Bcr-Abl tyrosine kinase inhibitors.

#ASH15

Mocuis CEO Speaks on Successful Panel at Bio International 2015

mocuis-bio-convention

Philadelphia, PA – June 19, 2015

On June 17th, the CEO of Mocuis Co., Ltd, Seungyun “Jenny” Jo (조승연), served on a panel to discuss bringing drugs from South Korea, China, and emerging markets, to higher regulated markets, such as the US and EU. The panel offered insights in improving the process from drug discovery to global commercialization. Topics included process efficiency, regulatory hurdles, partnership, funding, and licensing.

Joining Ms. Jo, was Blake Salisbury, Senior Director Corporate Business Development Emerging Markets Business Unit at Eli Lilly, Anthony Abruzzini, Vice President Global Strategic Drug Development at Quintiles, and moderator Richard Brown, General Partner at Plexus Ventures.

The Bio International Convention 2015 is the largest global event for the biotech industry and many of the biggest names in biotech and pharmaceuticals are in attendance. Over 15,000 attendees convened in Philadelphia, PA USA for this year’s event. Bio International Convention features over 3,100 companies from over 70 countries.

The speaker panel also presented Radotinib HCl (Supect®) as a case study in bringing a novel drug from South Korea to the US and EU. Supect® was developed by Ilyang Pharmaceutical in South Korea for the treatment of Chronic Myeloid Leukemia. It is the first Asian developed drug for treating leukemia.

Ms Jo said, “It is an exciting time for drug development in the emerging markets. We are seeing many great partnerships between Korean companies and multi-national pharmaceutical companies. With the commitment from the South Korean government’s Pharma 2020 Vision, expect Korea to continue driving innovation and global growth.”

About Mocuis Co., Ltd
Mocuis (모크스), is a specialty firm that advises and invests with partners in a tailored approach to maximize asset and stakeholder value. Mocuis focuses on quality businesses with leading positions in areas such as, biotech, pharmaceutical, and technology. With headquarters in Seoul and a satellite office in Chicago, Mocuis has key locations to build better international businesses through strategic partnerships, professional practices, effective capital, and global capabilities.

Mocuis CEO, Jenny (Seungyun) Jo Joins Interactive Speaker Panel at Bio International 2015

Join Mocuis at the Bio International Convention 2015 in Philadelphia

Our CEO, Jenny (Seungyun) Jo, will participate in an interactive speaker panel along with representatives from Eli Lilly and Quintiles. The session will cover bringing novel drugs from lower regulated territories, such as South Korea and China, to higher regulated territories.

Session Title

Reverse Innovation: Challenges in Making Drug Development a Two-Way Street

Session Description

Increasingly, companies in the emerging markets are conducting drug discovery to address local health needs. Helping to fuel this innovation are government investment in R&D and facilities, policy changes that favor regulatory review of novel products instead of approving the “nth” generic, and stronger IP protection. When novel, patented products achieve commercialization first in emerging markets, the innovators may try to attract foreign licensees, or may be approached by specialty pharmas looking to secure developed market rights to these low-risk assets. The session will examine this “reverse innovation” that’s moving novel products to – not from – advanced economies and the regulatory hurdles that are constricting this reverse new product flow.

Date

10:15 AM–11:30 AM Jun 17, 2015

Room 119A

Ability Level: all

Learn More>>>

Bio-2015

Supect® (Radotinib HCl) Completes Phase 3 Trials

Supect® (Radotinib HCl) Completes Phase 3 Trials. The trials began in August 2011 targeting 240 patients and in a multinational study onducted in South Korea, Thailand, Indonesia, and the Philippines. Supect is the first leukemia drug to be developed in Asia.

Supect is a second generation tyrosine kinase inhibitor approved in South Korea for the treatment of patients with Philadelphia positive chronic myeloid leukemia (Ph+ CML) without optimal response and/or tolerance to other Bcr-Abl tyrosine kinase inhibitors.

Supect-Radotinib-Packaging

Mocuis Will Attend the Bio International Convention 2014 in San Diego

Mocuis will attend the Bio International Convention 2014 in San Diego. The event is hosted by BIO (Biotechnology Industry Organization). Bio represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

If you would like to schedule a meeting, please email us at info@mocuis.com.

 

Mocuis Partners With Ilyang Pharm. from South Korea for the Out-licensing of Supect® (Radotinib HCl)

Seoul, South Korea – Mocuis Co., Ltd., has partnered with IL-Yang Pharmaceutical Co. Ltd. for the exclusive out-licensing of Supect ® (radotinib hydrochloride). Supect is a second generation tyrosine kinase inhibitor approved in South Korea for the treatment of patients with Philadelphia positive chronic myeloid leukemia (Ph+ CML) without optimal response and/or tolerance to other Bcr-Abl tyrosine kinase inhibitors. The product is currently in a multi-country Phase III clinical trial to assess its efficacy and safety in treating newly diagnosed CML patients as first-line therapy.

Jenny (Seungyun) Jo, CEO of Mocuis, stated, “Because of the emergence of resistance and intolerance to the first tyrosine kinase inhibitor, there is a constant need to develop novel products to treat Ph+ CML that are both effective and safe. IL-YANG developed radotinib HCl and introduced it in the South Korean market where it is co-marketed with Daewoong Pharmaceuticals. IL-Yang now seeks to have the product made available to treat Ph+ CML patients in all countries of the world.”

About Mocuis Co., Ltd.

Located in Seoul, South Korea and Chicago, Illinois, Mocuis (mō’kĭs), is a specialty firm that partners and advises clients with a cross-functional approach in order to maximize asset and stakeholder value. We focus on quality businesses with leading positions in areas such as, biotech, pharmaceutical, technology, real estate, and manufacturing.  Mocuis specializes in global strategy, market preparedness, alliance management, business development, marketing, funding and M&A. Visit www.mocuis.com for more information.

About IL-YANG Pharmaceutical Co., Ltd.

Founded in 1946, IL-Yang Pharmaceutical Co., Ltd. is one of the leading Korean pharmaceutical companies focusing on developing new chemical entities. The current pipeline includes novel compounds in the fields of oncology, autoimmune, anti-viral, and myocardial infarction. The company also produces a broad range of primary care and specialty pharmaceuticals, nutritionals and cosmetics for the Korean market. Visit www.ilyang.co.kr/english for more information.

Ilyang Logo